🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Chronic rejection in kidney transplants can lead to graft failure. NK cells play a key role in antibody-mediated rejection. Promising therapies like felzartamab, targeting NK cell function, show potential in addressing this challenge. Matthias Diebold # tinyurl.com/2af5k5tf

Our review on advances in the treatment of AAV is out now in NatRevRheumatol. It provides an update on currently used therapies and identified major innovations which will become relevant in the next couple of years! EUVAS nature.com/articles/s4158…

Excited to announce my candidacy for board member of the Young Professionals in Transplantation Committee! One of my goals would be to support the professional development of early-career physician-scientists in transplantation #ESOT #YPT #strongertogether

The May Monthly Issue for Transplant International is here, check it out: ➡️ fro.ntiers.in/vzSR Featuring the cover article by Georg A. Böhmig, Matthias Diebold, et al, 'Targeting CD38 in antibody-mediated rejection' ESOTtransplant